However, HCC therapy faces significant challenges, including therapy resistance driven by tumor heterogeneity, hypoxia, and alterations in signaling pathways such as PI3K/AKT/mTOR and Wnt/β-catenin [5,6]. This evidence concerns the gene AKT1 and hepatocellular carcinoma.